Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL28512738 | 1.00 | LMNA (0.56) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL7035160 | 1.00 | LMNA (0.56) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL8430202 | 1.00 | LMNA (0.56) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL2220986 | 1.00 | LMNA (0.56) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL124052 | 1.00 | LMNA (0.56) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL854170 | 1.00 | LMNA (0.56) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL21352472 | 0.97 | LMNA (0.53) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL21799190 | 0.97 | LMNA (0.53) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL6857287 | 0.94 | LMNA (0.50) | LMNAALDH1A1CA5ACA5BTHRB | |
| Glycerin SCHEMBL6292053 | 0.94 | LMNA (0.50) | LMNAALDH1A1CA5ACA5BTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767104-A | Bifunctional compounds and methods of use thereof | 百放英库医药科技(北京)有限公司 | 2021-12-07 | — | — | CN | claimed |
| CN-109053158-B | Thermosensitive ceramic powder, NTC thermosensitive chip, temperature sensor and preparation method | 深圳市汇北川电子技术有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-112618551-A | Pharmaceutical composition for relieving vasospasm and preparation method and application thereof | 泰达国际心血管病医院 | 2021-04-09 | — | — | CN | claimed |
| EP-1876232-B1 | NEW TRICHODERMA ATROVIRIDE STRAIN, CULTURE MEDIUM CONTAINING IT, AND USE OF THE STRAIN IN PARTICULAR AS A STIMULANT FOR THE GERMINATION AND/OR GROWTH OF PLANTS | NIXE (FR) | 2018-11-14 | — | — | EP | claimed |
| CN-108601765-A | Therapeutic agents for preterm birth management | 德克萨斯州大学系统董事会 | 2018-09-28 | — | — | CN | claimed |
| CN-108272833-A | A kind of ginkgo biloba p.e and its extracting method | 万邦德制药集团股份有限公司 | 2018-07-13 | — | — | CN | claimed |
| CN-108084031-A | A kind of preparation method of nitroglycerin | 广州白云山明兴制药有限公司 | 2018-05-29 | — | — | CN | claimed |
| CN-107412173-A | Anti-distort solid oral dosage form | 普渡制药公司 | 2017-12-01 | — | — | CN | claimed |
| US-9315749-B2 | Liquid fuel composition with alcohols of four carbon atoms and additives, with ignition by compression | FABRE JOSE ANTONIO (BR) | 2016-04-19 | — | — | US | claimed |
| EP-3004293-A2 | ADDITIVE FOR CETANE NUMBER INCREASE OF DIESEL FUELS AND BIO-DIESEL FUELS AND ITS USE | Slovenská Technická Univerzita v Bratislave Strojnicka Fakulta (SK) | 2016-04-13 | — | — | EP | claimed |
| US-20090087425-A1 | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease | TOPIGEN PHARMACEUTICALS INC. (CA) | 2009-04-02 | — | — | US | claimed |
| WO-2009037584-A2 | COMBINATION OF NITRODERIVATIZED STEROID AND BRONCHODILATOR FOR TREATING RESPIRATORY DISEASE | TOPIGEN PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | WO | claimed |
| EP-1746099-A1 | Mnk1 or Mnk2 inhibitors | DeveloGen Aktiengesellschaft (DE) | 2007-01-24 | — | — | EP | claimed |
| US-20060286158-A1 | Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents | CURE THERAPEUTICS, INC. | 2006-12-21 | — | — | US | claimed |
| EP-0627244-B1 | FIRE EXTINGUISHING COMPOSITION | LJUBERETSKOE N PROIZV (RU) | 2000-05-31 | — | — | EP | claimed |
| CN-1178070-A | Solutions for organ preservation during transplantations and operations | LIU CHUNJIANG (CN) | 1998-04-08 | — | — | CN | claimed |
| US-5545360-A | PYROLYSIS OF DROPLETS WHICH CONTAIN MIXTURE OF MAGNESIUM NITRATE, ALUMINUM NITRATE AND GLYCEROL, OR GLYCOL ADDITIVES, IN PRESENCE OF OXIDIZER OR REDUCING AGENT TO FORM BINARY OXIDE PARTICLES; HEAT TREATMENT | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1996-08-13 | — | — | US | claimed |
| US-5254570-A | Acyl derivative of dianhydrohexitols | PFIZER INC. (US) | 1993-10-19 | — | — | US | claimed |
| EP-0361156-B1 | PHARMACEUTICALS | Heinrich Mack Nachf. (DE) | 1993-03-10 | — | — | EP | claimed |
| EP-0361156-A2 | Pharmaceuticals | Heinrich Mack Nachf. (DE) | 1990-04-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087425-A1 | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease | HSD11B1, HSD11B2, CYP11B1 | LMNA 3384/4885ALDH1A1 1118/4885CA5A 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.